137 related articles for article (PubMed ID: 26085065)
1. N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase.
Adams BT; Niccoli S; Chowdhury MA; Esarik AN; Lees SJ; Rempel BP; Phenix CP
Chem Commun (Camb); 2015 Jul; 51(57):11390-3. PubMed ID: 26085065
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, kinetic evaluation and cell-based analysis of C-alkylated isofagomines as chaperones of β-glucocerebrosidase.
Hill T; Tropak MB; Mahuran D; Withers SG
Chembiochem; 2011 Sep; 12(14):2151-4. PubMed ID: 21751327
[No Abstract] [Full Text] [Related]
3. Rational design and synthesis of highly potent beta-glucocerebrosidase inhibitors.
Zhu X; Sheth KA; Li S; Chang HH; Fan JQ
Angew Chem Int Ed Engl; 2005 Dec; 44(45):7450-3. PubMed ID: 16231389
[No Abstract] [Full Text] [Related]
4. Conduritol aziridine: a new mechanism-based glucosidase inactivator.
Caron G; Withers SG
Biochem Biophys Res Commun; 1989 Aug; 163(1):495-9. PubMed ID: 2673241
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase enhancers for selected Gaucher disease genotypes by modification of α-1-C-substituted imino-D-xylitols (DIXs) by click chemistry.
Serra-Vinardell J; Díaz L; Casas J; Grinberg D; Vilageliu L; Michelakakis H; Mavridou I; Aerts JM; Decroocq C; Compain P; Delgado A
ChemMedChem; 2014 Aug; 9(8):1744-54. PubMed ID: 24976039
[TBL] [Abstract][Full Text] [Related]
6. Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease.
Alfonso P; Andreu V; Pino-Angeles A; Moya-García AA; García-Moreno MI; Rodríguez-Rey JC; Sánchez-Jiménez F; Pocoví M; Ortiz Mellet C; García Fernández JM; Giraldo P
Chembiochem; 2013 May; 14(8):943-9. PubMed ID: 23606264
[TBL] [Abstract][Full Text] [Related]
7. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
Trapero A; Llebaria A
Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
[TBL] [Abstract][Full Text] [Related]
8. Getting into the fold.
Brooks DA
Nat Chem Biol; 2007 Feb; 3(2):84-5. PubMed ID: 17235342
[No Abstract] [Full Text] [Related]
9. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?
Trapero A; Llebaria A
Future Med Chem; 2014 Jun; 6(9):975-8. PubMed ID: 25068980
[No Abstract] [Full Text] [Related]
10. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
Trapero A; González-Bulnes P; Butters TD; Llebaria A
J Med Chem; 2012 May; 55(9):4479-88. PubMed ID: 22512696
[TBL] [Abstract][Full Text] [Related]
11. Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.
Cheng WC; Weng CY; Yun WY; Chang SY; Lin YC; Tsai FJ; Huang FY; Chen YR
Bioorg Med Chem; 2013 Sep; 21(17):5021-8. PubMed ID: 23880081
[TBL] [Abstract][Full Text] [Related]
12. Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
Kato A; Miyauchi S; Kato N; Nash RJ; Yoshimura Y; Nakagome I; Hirono S; Takahata H; Adachi I
Bioorg Med Chem; 2011 Jun; 19(11):3558-68. PubMed ID: 21546253
[TBL] [Abstract][Full Text] [Related]
13. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease.
van Weely S; Brandsma M; Strijland A; Tager JM; Aerts JM
Biochim Biophys Acta; 1993 Mar; 1181(1):55-62. PubMed ID: 8457606
[TBL] [Abstract][Full Text] [Related]
15. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
Trapero A; Alfonso I; Butters TD; Llebaria A
J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
[TBL] [Abstract][Full Text] [Related]
16. In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Kuo CL; Kallemeijn WW; Lelieveld LT; Mirzaian M; Zoutendijk I; Vardi A; Futerman AH; Meijer AH; Spaink HP; Overkleeft HS; Aerts JMFG; Artola M
FEBS J; 2019 Feb; 286(3):584-600. PubMed ID: 30600575
[TBL] [Abstract][Full Text] [Related]
17. Recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model.
Lamghari M; Barrias CC; Sá Miranda C; Barbosa MA
Blood Cells Mol Dis; 2005; 35(3):348-54. PubMed ID: 16125984
[TBL] [Abstract][Full Text] [Related]
18. Chemical inhibition of β-glucocerebrosidase does not affect phagocytosis and early containment of Leishmania by murine macrophages.
Ribeiro H; Rocha MI; Castro H; Macedo MF
Exp Parasitol; 2020 Sep; 216():107939. PubMed ID: 32535115
[TBL] [Abstract][Full Text] [Related]
19. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease.
Berger J; Lecourt S; Vanneaux V; Rapatel C; Boisgard S; Caillaud C; Boiret-Dupré N; Chomienne C; Marolleau JP; Larghero J; Berger MG
Br J Haematol; 2010 Jul; 150(1):93-101. PubMed ID: 20507316
[TBL] [Abstract][Full Text] [Related]
20. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
